Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Emergency Medicine and Critical Care
- Neurology
- Breast Neoplasms
- Orthopedic Surgery
- Obstetrics and Gynecology
- Cardio-Thoracic Surgery
- Nuclear Medicine
- Hepatology
Abstract
Citation: Ann Clin Case Rep. 2022;7(1):2236.DOI: 10.25107/2474-1655.2236
First Reported Case of ‘High-Risk’ Protected PCI with Impella in a Very Old Patient with Multiple Comorbidities
Rao A1, Mehta H1, Reddy KVC1,2*, Hajari R3 and Ravishankar V4
1Department of Clinical and Interventional Cardiology, Lilavati Hospital and Research Center, India 2Department of Structural and Interventional Cardiology, Apollo Hospital, India 3Department of Cardiac Anesthesia, Lilavati Hospital and Research Center, India 4Department of Cardiovascular and Thoracic Surgery, Lilavati Hospital and Research Center, India
PDF Full Text Case Report | Open Access
Abstract:
Background: For a long time, high-risk and complex coronary interventions had been in the exclusive domain of cardiac surgeons. High-risk "protected" Percutaneous Coronary Intervention (PCI) using mechanical circulatory support (MCS) devices such as Impella have now emerged as a viable option particularly in high-risk patients with multiple comorbidities. Clinical Case: Here we present the first reported case in medical literature of the use of Impella device during a unprotected Left Main (LM) and complex bifurcation Percutaneous Coronary Intervention (PCI), in a 93 year old patient with multiple comorbidities. Conclusion: This case highlights the problems or difficulties encountered in using MCS in such patient subsets and giving some valuable lessons for its widespread use in the future.
Keywords:
Impella device; Complex percutaneous coronary intervention; CAD; MVD
Cite the Article:
Rao A, Mehta H, Reddy KVC, Hajari R, Ravishankar V. First Reported Case of ‘High-Risk’ Protected PCI with Impella in a Very Old Patient with Multiple Comorbidities. Ann Clin Case Rep. 2022; 7: 2236..